Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Fierce Pharma3d
Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...
Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak
A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...
Why Novo Nordisk Stock Is Falling Today
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.